SENOLYTIN-P1

1 study on SENOLYTIN-P1 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.

Bottom line: TitrateLab currently curates 1 dated study on SENOLYTIN-P1. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.

SENOLYTIN-P1 studies and clinical research

2026-04-23 PubMed · preclinical animal · n preclinical

Novel Peptide Senolytic Agent Reverses Brain Aging and Cognitive Decline in Mice

This study provides strong preclinical evidence for a novel therapeutic approach to combat brain aging and cognitive decline by targeting the FOXO4-p53 axis. The significant improvements in cognitive function and redu…

Research tools

Free, no account — handy when you're working with SENOLYTIN-P1.

Reconstitution calculator Bac water, concentration & insulin-unit math Verify a COA Look up a report number against our corpus

TitrateLab PRO

Unlock the complete evidence trail

Pro members save studies and unlock the full evidence breakdown and vendor lab data.

Complete vendor lab histories
Every linked certificate on file
Batch-level purity and quantity detail
Thousands of community reviews

Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.

$12 monthly or $33 lifetime

Create free account

TitrateLab

You must be 21 or older to enter.

TitrateLab provides research-use information on peptides for adults. Confirm your age to continue.

For research purposes only. Not for human consumption. By entering you agree to our Terms & Privacy.

SENOLYTIN-P1 studies and clinical research

Novel Peptide Senolytic Agent Reverses Brain Aging and Cognitive Decline in Mice

Research tools